Sartorius Stedim Biotech


13/04/21 -"Our target price upgrade is largely attributable to the higher DCF valuation, which now acknowledges the faster-than-expected and more profitable growth that Sartorius Stedim is poised for, courtesy ..."

Pages
59
Language
English
Published on
13/04/21
You may also be interested by these reports :
08/05/24
CZM reported soft Q2 results with both sales and adjusted EBIT missing the street’s expectations. The mid-single-digit sales decline was due to ...

08/05/24
We have maintained our assumptions based on the company’s planned €300m recap to be completed by the end of this year, but with an expected ...

07/05/24
CEO Helen Giza clarified that the implementation of the operating model, once announced, would be a marathon, not a sprint. She acknowledged ...

07/05/24
Amplifon’s Q1 results were in line with the company-compiled consensus. The mid-single-digit top-line growth was supported by the contributions from ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO